BioNTech Delivers First Patient Dose In Herpes Vaccine Clinical Trial
BioNTech has finally dosed the first patient with its Herpes Vaccine (BNT163) in a candidate clinical trial. According to the German Vaccine maker, “The vaccine is designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study.”
Continue Reading https://thetechwires.com
Join the Discussion